This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. The FDA cleared BrainsWay D treatment of Major Depression in patients who failed to respond to one or more anti-depressants in the current episode.
Shalvata Mental Health Center, Israel
11 March 2012
The purpose of this study is to evaluate the safety and anti-depressive response of the H1 Coil TMS Device in elderly patients suffering from major depressive episode.
A randomized, sham-controlled trial is now conducted at Shalvata Mental-Health Center. Its aim is to evaluate the efficacy and safety of H1-coil Deep TMS in subjects with Major Depression, currently treated by mood stabilizers.
Principal Investigator: Prof. Hilik Levkovitz